Skip to content

INTERLEUKIN GENETICS INC: 10-Q filed 2016-11-14

What INTERLEUKIN GENETICS INC reported in its quarterly report filed 2016-11-14 (fiscal Q3 2016): 32 published measures, 92 facts as tagged in accession 0001144204-16-134133.

This filing

Form
10-Q (quarterly report)
Filed
2016-11-14
Fiscal period
fiscal Q3 2016
Accession
0001144204-16-134133 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All INTERLEUKIN GENETICS INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2016-09-305,807,863USD
At 2015-12-316,491,520USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2016-09-307,144,504USD
At 2015-12-318,952,920USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-09-30-1,336,641USD
At 2015-12-31-2,461,400USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2016-09-304,344,296USD
At 2015-12-314,706,018USD
At 2015-09-306,270,644USD
At 2014-12-3111,466,807USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2016-07-01 to 2016-09-30-1,966,505USD92
2016-01-01 to 2016-09-30-5,571,442USD274
2015-01-01 to 2015-12-317,900,000USD365
2015-07-01 to 2015-09-30-2,025,510USD92
2015-01-01 to 2015-09-30-6,035,490USD273
2014-01-01 to 2014-12-316,300,000USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2016-01-01 to 2016-09-3054,526USD274
2015-01-01 to 2015-09-3041,057USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2016-07-01 to 2016-09-30734,468USD92
2016-01-01 to 2016-09-302,285,595USD274
2015-07-01 to 2015-09-30295,998USD92
2015-01-01 to 2015-09-301,075,261USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2016-09-30-134,559,767USD
At 2015-12-31-128,988,325USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2016-07-01 to 2016-09-300USD92
2016-01-01 to 2016-09-300USD274
2015-07-01 to 2015-09-300USD92
2015-01-01 to 2015-09-300USD273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2016-09-30537,214USD
At 2015-12-31643,900USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2016-01-01 to 2016-09-30642,726USD274
2015-01-01 to 2015-09-30651,791USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2016-07-01 to 2016-09-30-1,812,836USD92
2016-01-01 to 2016-09-30-5,117,359USD274
2015-07-01 to 2015-09-30-1,872,156USD92
2015-01-01 to 2015-09-30-5,579,401USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2016-09-305,208,856USD
At 2015-12-315,695,533USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2016-07-01 to 2016-09-3068,377USD92
2016-01-01 to 2016-09-30292,086USD274
2015-07-01 to 2015-09-30115,000USD92
2015-01-01 to 2015-09-30341,250USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2016-09-305,547,135USD
At 2015-12-315,477,936USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2016-09-30426,638USD
At 2015-12-31408,374USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2016-09-30267,102USD
At 2015-12-3145,973USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2016-07-01 to 2016-09-302,103,929USD92
2016-01-01 to 2016-09-306,077,455USD274
2015-07-01 to 2015-09-301,845,018USD92
2015-01-01 to 2015-09-305,668,930USD273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2016-09-3078,141USD
At 2015-12-31124,583USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2016-07-01 to 2016-09-30291,093USD92
2016-01-01 to 2016-09-30960,096USD274
2015-07-01 to 2015-09-30-27,138USD92
2015-01-01 to 2015-09-3089,529USD273

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2016-07-01 to 2016-09-30443,375USD92
2016-01-01 to 2016-09-301,325,499USD274
2015-07-01 to 2015-09-30323,136USD92
2015-01-01 to 2015-09-30985,732USD273

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2016-07-01 to 2016-09-301,677,467USD92
2016-01-01 to 2016-09-304,701,727USD274
2015-07-01 to 2015-09-301,413,702USD92
2015-01-01 to 2015-09-304,631,718USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2016-07-01 to 2016-09-30418,100USD92
2016-01-01 to 2016-09-301,350,641USD274
2015-07-01 to 2015-09-30411,902USD92
2015-01-01 to 2015-09-30978,970USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2016-09-30229,331,060shares
At 2015-12-31172,887,221shares

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2016-09-3033,792USD
At 2015-12-3158,879USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2016-09-3028,001USD
At 2015-12-3193,208USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2016-09-30591,570USD
At 2015-12-31497,688USD

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2016-07-01 to 2016-09-308,362USD92
2016-01-01 to 2016-09-3025,087USD274
2015-07-01 to 2015-09-3019,414USD92
2015-01-01 to 2015-09-3058,242USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2016-07-01 to 2016-09-30-153,669USD92
2016-01-01 to 2016-09-30-454,083USD274
2015-07-01 to 2015-09-30-153,354USD92
2015-01-01 to 2015-09-30-456,089USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-09-30221,129USD274
2015-01-01 to 2015-09-30-8,708USD273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-09-30-46,442USD274
2015-01-01 to 2015-09-30-12,482USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-09-3018,264USD274
2015-01-01 to 2015-09-3062,283USD273

Inspect the source

Entity
INTERLEUKIN GENETICS INC / CIK 0001037649
Captured
SEC response SHA-256
a1dec64965ae0507fde1f8bdab94feeb924a2817b4582e8fe10de362809c5bbd

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001037649.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))